Georg Daeschlein1, Matthias B Stope2, Denis Gümbel3,4, Bettina Suchy5, Lasse Wien5, Nadine Gelbrich5, Matthias Napp5, Axel Kramer6, Axel Ekkernkamp5,4. 1. Department of Dermatology, University Medicine Greifswald, Greifswald, Germany. 2. Department of Urology, University Medicine Greifswald, Greifswald, Germany. 3. Department of Trauma, Reconstructive Surgery and Rehabilitation Medicine, University Medicine Greifswald, Greifswald, Germany denis.guembel@uni-greifswald.de. 4. Department of Trauma and Orthopaedic Surgery, BG Klinikum Unfallkrankenhaus Berlin gGmbH, Berlin, Germany. 5. Department of Trauma, Reconstructive Surgery and Rehabilitation Medicine, University Medicine Greifswald, Greifswald, Germany. 6. Department of Hygiene and Environmental Medicine, University Medicine Greifswald, Greifswald, Germany.
Abstract
BACKGROUND/AIM: Cold atmospheric plasma (CAP) attenuates tumor cell proliferation and induces apoptosis in various cell lines. While exerting marginal effects on non-neoplastic cells this unfolds promising applications in cancer therapy. The aim of the study was to analyse the effects of different CAP sources and application times on osteosarcoma (OS) cells and non-malignant fibroblast cell proliferation. MATERIALS AND METHODS: U2-OS and 3-T-3 fibroblasts were treated with three different approved medical devices. Carrier gas-treated cells served as controls. Cell proliferation was determined by viable cell count at different time points after treatment. RESULTS: Control exposed U2-OS and 3-T-3 cells exhibited characteristic cell growth. CAP application of U2-OS and 3-T-3 cells attenuated proliferation rates up to 98%. Attenuation rates varied between cell lines, plasma sources and application times. CONCLUSION: CAP treatment attenuates cell proliferation of OS cancer cells and fibroblasts in a treatment time-dependent manner, whereby U2-OS cells appeared more sensitive to CAP treatment as 3T3 fibroblasts after 10 sec of treatment. Copyright
BACKGROUND/AIM: Cold atmospheric plasma (CAP) attenuates tumor cell proliferation and induces apoptosis in various cell lines. While exerting marginal effects on non-neoplastic cells this unfolds promising applications in cancer therapy. The aim of the study was to analyse the effects of different CAP sources and application times on osteosarcoma (OS) cells and non-malignant fibroblast cell proliferation. MATERIALS AND METHODS: U2-OS and 3-T-3 fibroblasts were treated with three different approved medical devices. Carrier gas-treated cells served as controls. Cell proliferation was determined by viable cell count at different time points after treatment. RESULTS: Control exposed U2-OS and 3-T-3 cells exhibited characteristic cell growth. CAP application of U2-OS and 3-T-3 cells attenuated proliferation rates up to 98%. Attenuation rates varied between cell lines, plasma sources and application times. CONCLUSION: CAP treatment attenuates cell proliferation of OS cancer cells and fibroblasts in a treatment time-dependent manner, whereby U2-OS cells appeared more sensitive to CAP treatment as 3T3 fibroblasts after 10 sec of treatment. Copyright
Authors: Benedikt Eggers; Matthias Bernhard Stope; Jana Marciniak; Werner Götz; Alexander Mustea; James Deschner; Marjan Nokhbehsaim; Franz-Josef Kramer Journal: Biomedicines Date: 2022-04-13
Authors: Josephine M Jacoby; Silas Strakeljahn; Andreas Nitsch; Sander Bekeschus; Peter Hinz; Alexander Mustea; Axel Ekkernkamp; Mladen V Tzvetkov; Lyubomir Haralambiev; Matthias B Stope Journal: Int J Mol Sci Date: 2020-06-23 Impact factor: 5.923
Authors: Lukas Feil; André Koch; Raphael Utz; Michael Ackermann; Jakob Barz; Matthias Stope; Bernhard Krämer; Diethelm Wallwiener; Sara Y Brucker; Martin Weiss Journal: Cancers (Basel) Date: 2020-04-23 Impact factor: 6.639
Authors: Benedikt Eggers; Matthias Bernhard Stope; Jana Marciniak; Alexander Mustea; James Deschner; Marjan Nokhbehsaim; Franz-Josef Kramer Journal: Cells Date: 2022-09-02 Impact factor: 7.666
Authors: Thomas Wenzel; Daniel A Carvajal Berrio; Christl Reisenauer; Shannon Layland; André Koch; Diethelm Wallwiener; Sara Y Brucker; Katja Schenke-Layland; Eva-Maria Brauchle; Martin Weiss Journal: Cancers (Basel) Date: 2020-01-22 Impact factor: 6.639
Authors: Lyubomir Haralambiev; Lasse Wien; Nadine Gelbrich; Jörn Lange; Sinan Bakir; Axel Kramer; Martin Burchardt; Axel Ekkernkamp; Denis Gümbel; Matthias B Stope Journal: Oncol Lett Date: 2019-11-19 Impact factor: 2.967